Drug Approval | May 20, 2026
Bayer’s stroke drug wins fast-track review in US
The development comes as stroke remains one of the world’s biggest health threats
The development comes as stroke remains one of the world’s biggest health threats
The approval enables the company to directly sell health insurance plans to individuals and families while integrating its managed healthcare delivery model into retail offerings
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
